Blood Journal
Leading the way in experimental and clinical research in hematology

Rational design and characterization of platelet factor 4 antagonists for the study of heparin-induced thrombocytopenia

  1. Bruce S. Sachais1,
  2. Ann H. Rux1,
  3. Douglas B. Cines1,
  4. Serge V. Yarovoi1,
  5. Lee I. Garner2,
  6. Stephen P. Watson2,
  7. Jillian L. Hinds1, and
  8. John J. Rux3
  1. 1Department of Pathology and Laboratory Medicine, Pearlman School of Medicine, University of Pennsylvania, Philadelphia, PA;
  2. 2Centre for Cardiovascular Sciences, Institute for Biomedical Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom; and
  3. 3In Silico Molecular LLC, Blue Bell, PA


Patients with heparin-induced thrombocytopenia (HIT) remain at risk for recurrent thromboembolic complications despite improvements in management. HIT is caused by antibodies that preferentially recognize ultralarge complexes (ULCs) of heparin and platelet factor 4 (PF4) tetramers. We demonstrated previously that a variant PF4K50E forms dimers but does not tetramerize or form ULCs. Here, we identified small molecules predicted to bind PF4 near the dimer-dimer interface and that interfere with PF4 tetramerization. Screening a library of small molecules in silico for binding at this site, we identified 4 compounds that inhibited tetramerization at micromolar concentrations, designated PF4 antagonists (PF4As). PF4As also inhibited formation of pathogenic ULCs, and 3 of these PF4As promoted the breakdown of preformed ULCs. To characterize the ability of PF4As to inhibit cellular activation, we developed a robust and reproducible assay that measures cellular activation by HIT antibodies via FcγRIIA using DT40 cells. PF4As inhibit FcγRIIA-dependent activation of DT40 cells by HIT antibodies as well as platelet activation, as measured by serotonin release. PF4As provide new tools to probe the pathophysiology of HIT. They also may provide insight into the development of novel, disease-specific therapeutics for the treatment of thromboembolic complications in HIT.

  • Submitted January 26, 2012.
  • Accepted March 12, 2012.
View Full Text